These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. An update on the epidemiology of aspirin-exacerbated respiratory disease. White AA Am J Rhinol Allergy; 2017 Sep; 31(5):299-301. PubMed ID: 28859704 [TBL] [Abstract][Full Text] [Related]
29. Epithelial dysregulation in chronic rhinosinusitis with nasal polyposis (CRSwNP) and aspirin-exacerbated respiratory disease (AERD). Kohanski MA; Cohen NA; Barrett NA J Allergy Clin Immunol; 2021 Nov; 148(5):1161-1164. PubMed ID: 34371082 [No Abstract] [Full Text] [Related]
30. Controversies in Allergy: Aspirin Desensitization or Biologics for Aspirin-Exacerbated Respiratory Disease-How to Choose. Laidlaw TM; Chu DK; Stevens WW; White AA J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1462-1467. PubMed ID: 34999274 [TBL] [Abstract][Full Text] [Related]
31. Nonsteroidal anti-inflammatory drugs-exacerbated respiratory disease in adolescents. Ertoy Karagol HI; Yilmaz O; Topal E; Ceylan A; Bakirtas A Int Forum Allergy Rhinol; 2015 May; 5(5):392-8. PubMed ID: 25755210 [TBL] [Abstract][Full Text] [Related]
32. Utility of nasal mucus inflammatory profile as a biomarker of nasal polyp regrowth in aspirin-exacerbated respiratory disease. Corey KB; Turner JH; Chowdhury NI; Chandra RK; Li P; Wu P; Cahill KN J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1644-1645.e1. PubMed ID: 35398556 [No Abstract] [Full Text] [Related]
33. The Effect of Aspirin on Moderate to Severe Asthmatic Patients with Aspirin Hypersensitivity, Chronic Rhinosinusitis, and Nasal Polyposis. Arshi S; Darougar S; Nabavi M; Bemanian MH; Fallahpour M; Shokri S; Ahmadian J; Molatefi R; Rekabi M; Moinfar Z; Hashemitari P; Eslami N Iran J Allergy Asthma Immunol; 2021 Jun; 20(3):287-293. PubMed ID: 34134450 [TBL] [Abstract][Full Text] [Related]
34. A retrospective analysis of esophageal eosinophilia in patients with aspirin-exacerbated respiratory disease. Eid RC; Palumbo ML; Laidlaw TM; Buchheit KM; Cahill KN J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1338-1340. PubMed ID: 30261317 [No Abstract] [Full Text] [Related]
35. Comprehensive Analysis of Nasal Polyps Reveals a More Pronounced Type 2 Transcriptomic Profile of Epithelial Cells and Mast Cells in Aspirin-Exacerbated Respiratory Disease. Bangert C; Villazala-Merino S; Fahrenberger M; Krausgruber T; Bauer WM; Stanek V; Campion NJ; Bartosik T; Quint T; Regelsberger G; Niederberger-Leppin V; Bock C; Schneider S; Eckl-Dorna J Front Immunol; 2022; 13():850494. PubMed ID: 35418991 [TBL] [Abstract][Full Text] [Related]
36. Perioperative mepolizumab in aspirin-exacerbated respiratory disease does not prevent nasal polyp regrowth. Supron AD; Bergmark RW; Roditi RE; Buchheit KM Ann Allergy Asthma Immunol; 2023 Sep; 131(3):384-386. PubMed ID: 37336258 [No Abstract] [Full Text] [Related]
37. Rhinosinusitis and nasal polyposis in aspirin sensitive and aspirin tolerant patients: are they different? Kowalski ML Thorax; 2000 Oct; 55 Suppl 2(Suppl 2):S84-6. PubMed ID: 10992569 [No Abstract] [Full Text] [Related]
38. Dupilumab as an adjunct to surgery in patients with aspirin-exacerbated respiratory disease. Patel P; Bensko JC; Bhattacharyya N; Laidlaw TM; Buchheit KM Ann Allergy Asthma Immunol; 2022 Mar; 128(3):326-328. PubMed ID: 34863953 [No Abstract] [Full Text] [Related]
39. Central compartment involvement in aspirin-exacerbated respiratory disease: the role of allergy and previous sinus surgery. DelGaudio JM; Levy JM; Wise SK Int Forum Allergy Rhinol; 2019 Sep; 9(9):1017-1022. PubMed ID: 31246375 [TBL] [Abstract][Full Text] [Related]
40. Heterogeneity of NSAID-Exacerbated Respiratory Disease: has the time come for subphenotyping? Kowalski ML Curr Opin Pulm Med; 2019 Jan; 25(1):64-70. PubMed ID: 30489335 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]